Janus Henderson Group
ARQT icon

Janus Henderson Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Janus Henderson Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.7M Buy
1,854,566
+24,505
+1% +$625K 0.02% 441
2025
Q4 		$53.2M Sell
1,830,061
-567,970
-24% -$14.5M 0.02% 403
2025
Q3 		$45.2M Buy
2,398,031
+134,071
+6% +$2.11M 0.02% 431
2025
Q2 		$31.8M Buy
2,263,960
+2,211,360
+4,204% +$31M 0.02% 478
2025
Q1 		$827K Hold
52,600
– – ﹤0.01% 1721
2024
Q4 		$732K Hold
52,600
– – ﹤0.01% 1838
2024
Q3 		$489K Hold
52,600
– – ﹤0.01% 2046
2024
Q2 		$489K Buy
+52,600
New +$476K ﹤0.01% 2000
2023
Q4 		– Sell
-22,724
Closed -$121K – 2552
2023
Q3 		$121K Buy
22,724
+9
+0% +$77 ﹤0.01% 2487
2023
Q2 		$217K Sell
22,715
-46
-0.2% -$511 ﹤0.01% 2412
2023
Q1 		$251K Buy
+22,761
New +$329K ﹤0.01% 2375

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group's ARQT Position: Q1 2026 in Review

Janus Henderson Group increased its Arcutis Biotherapeutics (ARQT) stake by 1.3% in Q1 2026, buying an estimated $625K and bringing the position to 1,854,566 shares worth $43.7M. The position accounts for 0.02% of the portfolio, ranked #441.

Janus Henderson Group first reported a position in ARQT in Q1 2023 and has held it in 11 quarters since. The position peaked at $53.2M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Janus Henderson Group held 1,854,566 shares of Arcutis Biotherapeutics worth $43.7M as of Q1 2026.
  • Janus Henderson Group bought 24,505 Arcutis Biotherapeutics shares in Q1 2026, an estimated $625K.
  • Arcutis Biotherapeutics made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #441 holding.
  • Janus Henderson Group first reported a position in Arcutis Biotherapeutics in Q1 2023 and has held it in 11 quarters since.
  • Janus Henderson Group's Arcutis Biotherapeutics position peaked at $53.2M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.